Clinical Utility Study for Exo-PDAC

Qure Healthcare

Status: Withdrawn

Conditions: Pancreas Cancer

Treatments: Other: Educational Materials for a new diagnostic test

Study type: Interventional

Funder types: Industry

Identifiers

NCT05702385

Pro00068105

Details and patient eligibility

About

This is a national-level research study of oncologists, interventional gastroenterologists, and primary care providers. The purpose of this study is to assess the clinical evaluation and management (drug, procedures, counseling and other) of a subset of common patient care indications.

Full description

The results of this study could contribute to improved quality of care for patients by encouraging better care practices and adherence to evidence-based guidance. The data from this study will be submitted to a national journal for publication. The study plans to enroll up to 250 physicians.

Upon consenting and agreeing to participate in this study, participants will be asked to care for 3 simulated patient cases, known as Clinical Performance and Value Vignettes (CPV®). CPV®s describe patients physicians typically encounter in their daily practice and are not meant to be difficult. In each vignette, physicians are asked to share their expected care through 5 domains: 1) history, 2) physical exam, 3) diagnostic workup, 4) diagnosis and 5) treatment and follow-up. Each case takes approximately 15-20 minutes to complete and we estimate the time commitment for each round of CPV® administration to be approximately 45 - 60 minutes. All responses to the cases will be completed online and will be kept confidential. Over 2 CPV® administration rounds, the total time to care for the simulated patients is estimated at 1.5-2 hours.

If physicians are randomized to an intervention group in this study, they will receive educational materials on a novel diagnostic test after the first round of CPV® administration. They are asked to review these materials before moving to the next CPV® administration round. The time to review educational materials is estimated to be approximately 15 minutes.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Board-certified for at least two years
• Averaging at least 20 hours per week of clinical and patient care duties over the last six months
• Routinely evaluate patients at risk for pancreatic cancer in their practice
• Practicing in the U.S.
• English speaking
• Access to the internet
• Informed, signed, and voluntarily consented to be in the study

Exclusion criteria

• Non-English speaking
• Unable to access the internet
• Not practicing in the U.S.
• Not averaging at least 20 hours per week of clinical or patient care duties over the last six months
• Previous exposure to the test
• Do not voluntarily consent to be in the study

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

0 participants in 3 patient groups

Standard Practice

No Intervention group

Description:

The control group treats their simulated patients using standard practice and has no introduction to the new diagnostic test.

Intervention Group 1 - Test Results Given

Experimental group

Description:

Intervention Group 1 will receive information regarding the test and will be given the test results, whether selected or not, in Round 2 of CPV administration.

Treatment:

Other: Educational Materials for a new diagnostic test

Intervention Group 2 - Test Results Optional

Experimental group

Description:

Intervention Group 2 will receive information regarding the test and will be given the test results if selected in Round 2 of CPV administration.

Treatment:

Other: Educational Materials for a new diagnostic test